Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 4/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824960 | 1.00 | TTR (0.58) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL30279751 | 0.95 | TTR (0.58) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL17201734 | 0.95 | TTR (0.58) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL17201735 | 0.95 | TTR (0.58) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL25612098 | 0.91 | TTR (0.56) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL23580912 | 0.90 | TTR (0.54) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL30279790 | 0.90 | TTR (0.54) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL23580907 | 0.90 | TTR (0.54) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL17208338 | 0.89 | PTGES (0.55) | TTRCYP19A1ALOX5PTGS2PTGS1 | |
| SCHEMBL13824951 | 0.89 | TTR (0.53) | TTRCYP19A1ALOX5PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634375-B2 | Prenylated hydroxystilbenes | Kynan Duke IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220380285-A1 | PRENYLATED HYDROXYSTILBENES | Kynan Duke IP, LLC (US) | 2022-12-01 | — | — | US | disclosed |
| US-11352310-B2 | Prenylated hydroxystilbenes | Kynan Duke IP, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| EP-2709975-B1 | PRENYLATED HYDROXYSTILBENES | KYNAN DUKE IP LLC (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20200331833-A1 | PRENYLATED HYDROXYSTILBENES | THE UNIVERSITY OF SYDNEY (AU) | 2020-10-22 | — | — | US | disclosed |
| CN-107266297-B | Prenylated hydroxystilbenes, pharmaceutical compositions containing the same, use and preparation method thereof | 悉尼大学 | 2020-10-16 | — | — | CN | disclosed |
| US-10696615-B2 | Prenylated hydroxystilbenes | THE UNIVERSITY OF SYDNEY (AU) | 2020-06-30 | — | — | US | disclosed |
| US-20190194105-A1 | PRENYLATED HYDROXYSTILBENES | THE UNIVERSITY OF SYDNEY (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10196335-B2 | Prenylated hydroxystilbenes | THE UNIVERSITY OF SYDNEY (AU) | 2019-02-05 | — | — | US | disclosed |
| US-20150307429-A1 | PRENYLATED HYDROXYSTILBENES | Kynan Duke IP, LLC | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196335-B2 | Prenylated hydroxystilbenes | HMGB2, CYP51A1, CYP8B1 | TTR 741/4885CYP19A1 212/4885ALOX5 418/4885 |
| US-20200331833-A1 | PRENYLATED HYDROXYSTILBENES | HSD11B1, HSD3B1, CYP8B1 | TTR 1499/4885CYP19A1 64/4885ALOX5 1677/4885 |
| US-20220380285-A1 | PRENYLATED HYDROXYSTILBENES | HSD11B1, HSD3B1, CYP8B1 | TTR 1499/4885CYP19A1 64/4885ALOX5 1677/4885 |
| US-20150307429-A1 | PRENYLATED HYDROXYSTILBENES | HMGB2, CYP51A1, CYP8B1 | TTR 741/4885CYP19A1 212/4885ALOX5 418/4885 |
| US-10696615-B2 | Prenylated hydroxystilbenes | HSD11B1, CYP8B1, NR1H2 | TTR 2048/4885CYP19A1 79/4885ALOX5 2768/4885 |
| US-11352310-B2 | Prenylated hydroxystilbenes | HSD11B1, HSD3B1, CYP8B1 | TTR 1499/4885CYP19A1 64/4885ALOX5 1677/4885 |
| US-20190194105-A1 | PRENYLATED HYDROXYSTILBENES | HSD11B1, CYP8B1, NR1H2 | TTR 2048/4885CYP19A1 79/4885ALOX5 2768/4885 |
| US-11634375-B2 | Prenylated hydroxystilbenes | HCLS1, IWS1, UTS2R | TTR 4316/4885CYP19A1 1298/4885ALOX5 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.